Myriad Genetics reports Q3 adjusted EPS 6c, consensus 2c
Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...
Business Wire8h
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...
Myriad: Q3 Earnings Snapshot
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...
Business Insider16h
Myriad Genetics Inc. Q3 Earnings Summary
(RTTNews) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN): Earnings: -$22.1 million in Q3 vs. -$61.3 million in the same period last year. EPS: -$0.24 in Q3 vs. -$0.75 in the same ...
Taiwan News22h
Cardiovascular Genetic Testing Market Analysis, Disease Focus, Technology, Testing Types, Applications, and Regional Forecasts 2024-2032
Report Ocean has published a new report on the Cardiovascular Genetic Testing Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report ...